Vident Advisory’s Immunovant IMVT Stock Holding History

Vident Advisory’s Portfolio IMVT Stock Details IMVT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$339K	Sell	8,794 -217	-2%	-$6.61K	﹤0.01%	1561
2026 Q1	$224K	Buy	+9,011	New	+$233K	﹤0.01%	1636

Other funds holding IMVT

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vident Advisory's IMVT Position: Q2 2026 in Review

Vident Advisory reduced its Immunovant (IMVT) stake by 2.4% in Q2 2026, selling an estimated $6.61K and leaving 8,794 shares worth $339K. The position accounts for ﹤0.01% of the portfolio, ranked #1561.

Vident Advisory first reported a position in IMVT in Q1 2026 and has held it in 2 quarters since. 226 funds tracked by Wall St. Rank hold IMVT as of Q2 2026.

Vident Advisory held 8,794 shares of Immunovant worth $339K as of Q2 2026.
Vident Advisory sold 217 Immunovant shares in Q2 2026, an estimated $6.61K.
Immunovant made up ﹤0.01% of Vident Advisory's portfolio in Q2 2026, its #1561 holding.
Vident Advisory first reported a position in Immunovant in Q1 2026 and has held it in 2 quarters since.
226 funds tracked by Wall St. Rank held Immunovant as of Q2 2026.

Based on Vident Advisory's 13F filing for Q2 2026, filed 12 Aug 2026.